MedTrace Logo

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

NCT03887741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-12-31

No results posted yet for this study

Summary

Determine safety of plasma infusion or exchange in APOE 44 patients.

Conditions

Interventions

BIOLOGICAL

Plasmapheresis

Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma

BIOLOGICAL

Plasma infusion

Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months

Sponsors & Collaborators

Principal Investigators

  • Neill R Graff-Radford · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2024-02-16
Completion
2024-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03887741 on ClinicalTrials.gov